Supreme Court Decision Raises Questions of the Validity of Many Bioscience Patents: Did the Invention “Add Enough?”


On Tuesday, March 20, 2012, the U.S. Supreme Court issued its decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc. 566 U.S. ____ (2012). In a unanimous decision, the Supreme Court sided with Mayo and held that method claims involving administering a drug to a patient and determining the effect were not patentable subject matter. The court concluded that the method was directed to a “law of nature” and therefore not patentable. The court reasoned that the Prometheus patent added nothing of significance to the natural correlation between drug dosages and drug metabolite levels and that the patent otherwise had the effect of stifling future innovation in this area. The implications of this case are significant for certain segments of the pharma and biotech industries, particularly those wishing to obtain or enforce patents with certain types of diagnostic claims.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Snell & Wilmer | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.